The Clinical Efficacy And Prognostic Factors Of Percutaneous Biliary Stent Implantation Combined With ¹²⁵I Seed Intracavitary Irradiation In The Treatment Of Cholangiocarcinoma

Objective To evaluate the clinical efficacy of percutaneous biliary stent implantation combined with ¹²⁵I seed intracavitary irradiation in the treatment of cholangiocarcinoma and to explore the potential prognostic factors.Methods The clinical data of 105 patients with cholangiocarcinoma treated with percutaneous biliary stent implantation combined with ¹²⁵I seed intracavitary irradiation from January 2012 to January 2017 in our department were retrospectively analyzed.Levels of alanine aminotransferase（ALT）,aspartate aminotransferase（AST）,Total bilirubin（TBIL）,an albumin（ALB）were compared between before and after the treatment（1 month,3 month,and 6 months postoperatively）.The primary outcome was overall survival（OS）,which was estimated by the Kaplan–Meier method and Cox regression analysis.Results The levels of ALT,AST and TBIL significantly reduced and the ALB significantly increased after the operation.The median survival time was 12 months and the one-year survival rate was 57.4%.The preoperative CA19-9,TBIL,and ALB were found to be associated with OS by the log-rank test and univariate analysis.Multivariate Cox analysis further identified elevated levels of CA19-9 and TBIL as significant factors for predicting poor OS.Conclusion For patients with cholangiocarcinoma who can not undergo radical surgery,percutaneous biliary stent implantation combined with ¹²⁵I seed intracavitary irradiation is an effective treatment.Preoperative CA19-9 and TBIL may be independent prognostic risk factors for these patients.